Market Overview

Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug

Share:
Credit Suisse Lifts Teva Price Target, Says Execution Is Key For Migraine Drug

FDA approval of Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE: TEVA)'s migraine preventive medication Ajovy led Credit Suisse to raise its price target for the stock Monday. 

The Analyst

Credit Suisse analyst Vamil Divan maintained a Neutral rating on the shares of Teva and increased the price target from $23 to $26.

The Thesis

The FDA approval for Teva's Ajovy is an important potential growth driver, even as the company battles challenges it is facing with Copaxone, U.S. generics and its bloated debt load, Divan said in a Monday note. (See the analyst's track record here.) 

Credit Suisse moved up its launch timing estimate from the second half of 2019 to the fourth quarter of 2018 and increased the peak sales estimate due to the inclusion of quarterly dosing in the label.

As opposed to Amgen, Inc. (NASDAQ: AMGN)-Novartis AG (ADR) (NYSE: NVS) combo's drug and Eli Lilly And Co (NYSE: LLY)'s pipeline candidate, Ajovy is also approved in quarterly dosing, the analyst said. Ajovy comes in a pre-filled syringe as opposed to the auto-injector setup of competitors, he said. 

Divan said he expects a positive stock reaction. Credit Suisse's new price target accounts for the recent approval of Teva's generic EpiPen and near-term currency headwinds, he said. 

The analyst said he is watching how Teva markets this important asset in the coming months before becoming constructive on the stock's longer-term outlook.

Credit Suisse nudged down its EPS estimate for 2018 from $2.79 to $2.78 and lifted estimates for 2019 and 2020 from $2.82 and $2.79, respectively, to $2.88 and $2.89.

The Price Action

Teva shares were trading up 2.58 percent to $23.44 at the time of publication Monday. 

Related Links:

New Class of Migraine Drug Creates Four-Way Pharma Development Race

The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Latest Ratings for TEVA

DateFirmActionFromTo
Aug 2020BarclaysUpgradesUnderweightEqual-Weight
Aug 2020SVB LeerinkMaintainsMarket Perform
Jul 2020Goldman SachsInitiates Coverage OnNeutral

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Credit Suisse Vamil DivanAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
AAPDA DavidsonInitiates Coverage On154.0
PEGAJP MorganInitiates Coverage On128.0
MBIIAegis CapitalMaintains1.7
ACCDCredit SuisseMaintains40.0
TPRCredit SuisseMaintains17.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com